Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib

Pediatr Blood Cancer. 2020 May;67(5):e28200. doi: 10.1002/pbc.28200. Epub 2020 Feb 9.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Amino Acid Substitution
  • Histiocytic Sarcoma* / drug therapy
  • Histiocytic Sarcoma* / genetics
  • Histiocytic Sarcoma* / metabolism
  • Histiocytic Sarcoma* / pathology
  • Humans
  • Imidazoles / administration & dosage*
  • Infant
  • Male
  • Mutation, Missense*
  • Neoplasms, Second Primary* / drug therapy
  • Neoplasms, Second Primary* / genetics
  • Neoplasms, Second Primary* / metabolism
  • Neoplasms, Second Primary* / pathology
  • Oximes / administration & dosage*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
  • Proto-Oncogene Proteins B-raf* / genetics
  • Proto-Oncogene Proteins B-raf* / metabolism
  • Pyridones / administration & dosage*
  • Pyrimidinones / administration & dosage*

Substances

  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib